InvestorsHub Logo
Followers 20
Posts 1676
Boards Moderated 0
Alias Born 07/09/2005

Re: None

Thursday, 04/08/2021 11:23:01 AM

Thursday, April 08, 2021 11:23:01 AM

Post# of 137
04/08/2021
Hookipa Pharma initiated with an Overweight at Morgan Stanley Morgan Stanley analyst Vikram Purohit initiated coverage of Hookipa Pharma with an Overweight rating and $19 price target. Hookipa is developing candidates for cancer and infectious disease using its arenavirus platform and its initial clinical data for HB-201 in HPV16+ cancer provides early proof-of-concept, Purohit tells investors. The analyst estimates peak product sales of HB-201 in HPV16+ head and neck cancer of about $400M in 2030, assuming a launch in 2024 and assigning the program 75% odds of success. Overweight and $19 PT.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HOOK News